Abstract
MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma
cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression.
Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple
glucose-avid plasmacytomas were treated by intravenous infusion of 1011 TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded
to therapy with M protein reduction and resolution of bone marrow plasmacytosis. Further,
one patient experienced durable complete remission at all disease sites. Tumor targeting
was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas.
Toxicities resolved within the first week after therapy. Oncolytic viruses offer a
promising new modality for the targeted infection and destruction of disseminated
cancer.
Abbreviations and Acronyms:
ASCT (autologous stem cell transplant), Edm (Edmonston), FDG (fluorodeoxyglucose), GFP (green fluorescent protein), M-protein (monoclonal protein), MM (multiple myeloma), MV (measles virus), MV-NIS (measles virus encoding human sodium iodide symporter), NIS (sodium iodide symporter), OV (oncolytic virus), PET (Positron emission tomography), PRN (plaque reduction neutralization), SPECT (single-photon emission computed tomography), TCID50 (50% tissue culture infectious dose)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Mayo Clinic ProceedingsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Oncolytic virotherapy.Nat Biotechnol. 2012; 30: 658-670
- Trial watch: oncolytic viruses for cancer therapy.Oncoimmunology. 2013; 2: e24612
- Oncolytic viruses for induction of anti-tumor immunity.Curr Pharm Biotechnol. 2012; 13: 1750-1760
- An overview of the progress in the treatment of multiple myeloma.Exp Rev Hematol. 2014; 7: 5-7
- Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.Blood. 2004; 103: 1641-1646
- Virology of measles virus.J Infect Dis. 1994; 170: S15-S23
- Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.Clin Pharmacol Ther. 2007; 82: 700-710
- Oncolytic measles virus targets high CD46 expression on multiple myeloma cells.Exp Hematol. 2006; 34: 713-720
- Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.Gene Ther. 2007; 14: 324-333
- Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.Mol Ther. 2010; 18: 1155-1164
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma. ClinicalTrials.gov Identifier: NCT00450814. ClinicalTrials.gov website. http://clinicaltrials.gov/show/NCT00450814%20MC038C%20P30CA015083%20MC038C%2006-005263%20NCI-2009-01194%20NCT00450814. Updated March 20, 2014. Accessed April 14, 2014.
- Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.Mayo Clin Proc. 2013; 88: 360-376
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial [published correction appears in Lancet Oncol. 2010;11(1):14].Lancet Oncol. 2010; 11: 29-37
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.Leukemia. 2009; 23: 1337-1341
- Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.Nature. 2011; 477: 99-102
- Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.Mol Ther. 2007; 15: 123-130
- Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies.Cancer Gene Ther. 2010; 17: 792-802
- The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.Gene Ther. 2010; 17: 1465-1475
- Potent oncolytic activity of human enteroviruses against human prostate cancer.Prostate. 2008; 68: 577-587
- Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters.Plos One. 2013; 8: e73759
Article Info
Publication History
Published online: May 13, 2014
Footnotes
For editorial comment, see page 863
Grant Support: This work was supported by funds from the National Institutes of Health/National Cancer Institute (grants R01CA125614 and R01CA168719 ), Al and Mary Agnes McQuinn, the Harold W. Siebens Foundation, and the Richard M. Schulze Family Foundation. The National Cancer Institute RAID (Rapid Access to Intervention Development) Program supported MV-NIS manufacture and toxicology/pharmacology studies.
Potential Competing Interests: Drs Russell, Federspiel, and Peng and Mayo Clinic have a financial interest in the technology used in this research.
Identification
Copyright
© 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
